Health
Gout medication reduces major cardiovascular events in heart patients – News-Medical.Net
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Reviewed by Emily Henderson, B.Sc.Aug 31 2020
Colchicine reduces the risk of major cardiovascular events in patients with chronic coronary disease, according to results of the LoDoCo2 trial presented in a Hot Line session today at ESC Congress 2020.
Over a decade, more than one in three heart patients will have another heart attack or stroke, or die from heart disease, despite taking preventive medication. Our study shows that this could be reduced to one in four with the addition of low-dose …
-
Business21 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News20 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General15 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News17 hours agoTips to improve engagement – Proctor